CA2813752A1 - Polypeptides and their use in treating and limiting respiratory syncytial virus infection - Google Patents

Polypeptides and their use in treating and limiting respiratory syncytial virus infection Download PDF

Info

Publication number
CA2813752A1
CA2813752A1 CA2813752A CA2813752A CA2813752A1 CA 2813752 A1 CA2813752 A1 CA 2813752A1 CA 2813752 A CA2813752 A CA 2813752A CA 2813752 A CA2813752 A CA 2813752A CA 2813752 A1 CA2813752 A1 CA 2813752A1
Authority
CA
Canada
Prior art keywords
polypeptide
rsv
seq
subject
ffl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2813752A
Other languages
English (en)
French (fr)
Inventor
William R. Schief
David Baker
Bruno E. Correia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington Center for Commercialization
Original Assignee
University of Washington Center for Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington Center for Commercialization filed Critical University of Washington Center for Commercialization
Publication of CA2813752A1 publication Critical patent/CA2813752A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2813752A 2010-10-06 2011-10-06 Polypeptides and their use in treating and limiting respiratory syncytial virus infection Pending CA2813752A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39059110P 2010-10-06 2010-10-06
US61/390,591 2010-10-06
PCT/US2011/055113 WO2012048115A2 (en) 2010-10-06 2011-10-06 Polypeptides and their use in treating and limiting respiratory syncytial virus infection

Publications (1)

Publication Number Publication Date
CA2813752A1 true CA2813752A1 (en) 2012-04-12

Family

ID=44993163

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2813752A Pending CA2813752A1 (en) 2010-10-06 2011-10-06 Polypeptides and their use in treating and limiting respiratory syncytial virus infection

Country Status (7)

Country Link
US (1) US9718862B2 (enExample)
EP (1) EP2625194B1 (enExample)
JP (1) JP6023061B2 (enExample)
CN (1) CN103282378B (enExample)
AU (1) AU2011311946B8 (enExample)
CA (1) CA2813752A1 (enExample)
WO (1) WO2012048115A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6023061B2 (ja) 2010-10-06 2016-11-09 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーションＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｗａｓｈｉｎｇｔｏｎ Ｔｈｒｏｕｇｈ Ｉｔｓ Ｃｅｎｔｅｒ Ｆｏｒ Ｃｏｍｍｅｒｃｉａｌｉｚａｔｉｏｎ ポリペプチド、ならびに呼吸器多核体ウイルス感染症の治療および制限における該ポリペプチドの使用
US9701720B2 (en) 2012-04-05 2017-07-11 University Of Washington Through Its Center For Commercialization Epitope-scaffold immunogens against respiratory syncytial virus (RSV)
WO2017081082A2 (en) * 2015-11-09 2017-05-18 Curevac Ag Optimized nucleic acid molecules
SG11201908999QA (en) * 2017-04-04 2019-10-30 Univ Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN110891592B (zh) 2017-06-14 2024-08-13 维罗米蒂克斯股份公司 用于保护免受呼吸道合胞病毒的环状肽
EP3897708A1 (en) 2018-12-20 2021-10-27 Virometix AG Lipopeptide building blocks and synthetic virus-like particles
CN110853704B (zh) * 2019-11-11 2020-11-06 腾讯科技（深圳）有限公司 蛋白质数据获取方法、装置、计算机设备及存储介质

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
PL192016B1 (pl) 1998-11-30 2006-08-31 Cytos Biotechnology Ag Kompozycja, sposób wytwarzania sztucznego, uporządkowanego i powtarzalnego układu antygenu, zastosowanie kompozycji oraz kompozycja szczepionki
US6955717B2 (en) 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
US7097841B2 (en) 2002-05-10 2006-08-29 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20100068217A1 (en) 2006-08-25 2010-03-18 Kwong Peter D Epitope-transplant scaffolds and their use
KR101617895B1 (ko) 2007-12-24 2016-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 ｒｓｖ 항원
US20120034254A1 (en) 2008-02-07 2012-02-09 Kwong Peter D Antigenic cloaking and its use
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
JP6023061B2 (ja) 2010-10-06 2016-11-09 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーションＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｗａｓｈｉｎｇｔｏｎ Ｔｈｒｏｕｇｈ Ｉｔｓ Ｃｅｎｔｅｒ Ｆｏｒ Ｃｏｍｍｅｒｃｉａｌｉｚａｔｉｏｎ ポリペプチド、ならびに呼吸器多核体ウイルス感染症の治療および制限における該ポリペプチドの使用
US9701720B2 (en) 2012-04-05 2017-07-11 University Of Washington Through Its Center For Commercialization Epitope-scaffold immunogens against respiratory syncytial virus (RSV)

Also Published As

Publication number Publication date
AU2011311946A1 (en) 2013-05-02
WO2012048115A2 (en) 2012-04-12
US20130280262A1 (en) 2013-10-24
JP6023061B2 (ja) 2016-11-09
WO2012048115A3 (en) 2012-06-21
US9718862B2 (en) 2017-08-01
EP2625194B1 (en) 2015-08-12
EP2625194A2 (en) 2013-08-14
CN103282378A (zh) 2013-09-04
CN103282378B (zh) 2015-03-11
JP2014502143A (ja) 2014-01-30
AU2011311946B2 (en) 2014-10-02
AU2011311946B8 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
US20250368690A1 (en) Prefusion rsv f proteins and their use
US10858400B2 (en) Prefusion RSV F proteins and their use
Malladi et al. Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment
AU2011311946B8 (en) Polypeptides and their use in treating and limiting respiratory syncytial virus infection
McLellan et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus
AU2018249533B2 (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
TWI663175B (zh) 穩定化可溶性融合前ｒｓｖ ｆ多肽
US9701720B2 (en) Epitope-scaffold immunogens against respiratory syncytial virus (RSV)
EP4142785A2 (en) Recombinant human metapneumovirus f proteins and their use
KR20230009445A (ko) 안정화된 코로나바이러스 스파이크 단백질 융합 단백질
CN118772250B (zh) 一种rsv f蛋白突变体及其制法与应用
WO2013152169A1 (en) Polypeptides and their use in treating metapneumovirus (mpv) infection
CN121293297B (zh) 一种hiv纳米颗粒疫苗
US20250188131A1 (en) Viral proteins and nanostructures and uses thereof
WO2018175518A1 (en) Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv)
RU2844177C2 (ru) Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение
CN118725052A (zh) 具有稳定融合前构象的呼吸道合胞病毒f蛋白

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160719